ARS Pharmaceuticals
SPRY
64 hedge funds and large institutions have $73.3M invested in ARS Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 14 increasing their positions, 23 reducing their positions, and 26 closing their positions.
2.67% less ownership
Funds ownership: 76.81% → 74.14% (-2.7%)
9% less funds holding
Funds holding: 70 → 64 (-6)
12% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 26
23% less capital invested
Capital invested by funds: $94.7M → $73.3M (-$21.4M)
28% less call options, than puts
Call options by funds: $2.92M | Put options by funds: $4.07M
39% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$5.38M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$3.44M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.65M |
| 4 |
Millennium Management
New York
|
+$1.59M |
| 5 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$1.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$10.4M |
| 2 |
BlackRock
New York
|
-$3.14M |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$1.22M |
| 4 |
State Street
Boston,
Massachusetts
|
-$965K |
| 5 |
Two Sigma Investments
New York
|
-$724K |
SPRY Hedge Fund Activity: Q2 2022 in Review
64 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q2 2022, worth a combined $73.3M — down 23% from $94.7M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of SPRY and 23 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 14 added.
The largest buyer was K2 Principal Fund, opening a new position worth an estimated $5.38M. The largest seller was Wasatch Advisors, exiting entirely with an estimated $10.4M sold.
- 64 institutional investors held ARS Pharmaceuticals (SPRY) as of Q2 2022, down from 70 in Q1 2022.
- Funds reported $73.3M of ARS Pharmaceuticals stock for Q2 2022, down 23% quarter-over-quarter.
- 23 funds opened new ARS Pharmaceuticals positions in Q2 2022 and 26 closed out, a net change of -3 holders.
- The largest ARS Pharmaceuticals buyer in Q2 2022 was K2 Principal Fund, an estimated $5.38M added.
- The largest ARS Pharmaceuticals seller in Q2 2022 was Wasatch Advisors, an estimated $10.4M sold.
Based on aggregated 13F filings for Q2 2022.